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The complement system serves an important
role in clearance of pathogens, immune com-
plexes, and apoptotic cells present in the circu-
lation. Complement fragments deposited on
the particle surface serve as targets for comple-
ment receptors present on phagocytic cells.
Although Kupffer cells, the liver resident macro-
phages, play a dominant role in clearing
particles in circulation, complement receptors
involved in this process have yet to be identi-
fied. Here we report the identification and char-
acterization of a Complement Receptor of the
Immunoglobulin superfamily, CRIg, that binds
complement fragments C3b and iC3b. CRIg ex-
pression on Kupffer cells is required for efficient
binding and phagocytosis of complement C3-
opsonized particles. In turn, Kupffer cells from
CRIg-deficient mice are unable to efficiently
clear C3-opsonized pathogens in the circula-
tion, resulting in increased infection andmortal-
ity of the host. CRIg therefore represents a dom-
inant component of the phagocytic system
responsible for rapid clearance of C3-opson-
ized particles from the circulation.
INTRODUCTION
The liver plays a dominant role in the clearance of particles
from the bloodstream through Kupffer cells (KCs), which
represent themajor phagocytic constituent of the reticulo-
endothelial system (Benacerraf et al., 1959). KCs are stra-
tegically positioned in liver sinusoids to efficiently phago-
cytose pathogens from portal and arterial blood,
preventing infection of various organs. Phagocytosis ofcirculating pathogens by tissue resident macrophages is
primarily dependent on the presence of Fc receptors (re-
viewed by Ravetch and Bolland, 2001) and receptors for
complement components (Brown, 1991). In the absence
of antibodies, complement serves as the dominant opso-
nin contributing to pathogen clearance by phagocytes.
Complement component C3 is central to the activation
of all three complement pathways: the alternative, classi-
cal, and mannose binding lectin pathways (reviewed by
Walport, 2001a, 2001b). C3 binds to bacterial surfaces
via a thioester bond after cleavage to C3b, a subunit of ac-
tive C3 convertase. This step catalyzes the cleavage of
additional C3 molecules that then serves as a multivalent
ligand for complement receptors (CRs) expressed on
phagocytic cells (Pangburn and Muller-Eberhard, 1980).
Mice and humans lacking C3 are highly susceptible to
bacterial and viral infections (reviewed by Colten and
Rosen, 1992), demonstrating the central importance of
C3 in the innate immune defense.
Four complement C3 fragment receptors, CR1 (CD35),
CR2 (CD21), CR3 (CD11b/CD18), and CR4 (CD11c/
CD18), have been described to date (reviewed by Holers
et al., 1992). In the mouse, CR1/2 is expressed on B cells
and follicular dendritic cells (Fang et al., 1998) and CR4
on dendritic cells (Metlay et al., 1990), but none of these
receptors have been described as functional complement
receptors on KCs. Low levels of CR3 are expressed on
KCs but do not appear to be involved in the rapid hepatic
clearance of complement C3-opsonized pathogens
(Gregory et al., 2002; Wu et al., 2003). Thus, the putative
receptor on KCs critical for complement-mediated clear-
ance of circulating pathogens has so far not been de-
scribed.
Here we report the identification of a novel complement
receptor, CRIg, which is uniquely expressed on tissue res-
ident and sinusoidal macrophages and whose structure
and function are conserved in humans and mice. In con-
trast to known complement receptors described to date,
CRIg is found on a constitutively recycling pool ofCell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc. 915
membrane vesicles and participates in the internalization
of C3-opsonized particles from the circulation by KCs.
Mice lacking CRIg are unable to efficiently clear patho-
gens in the circulation, demonstrating that CRIg is a critical
component of the innate immune system.
RESULTS
CRIg Is Expressed on a Subset of Tissue
Resident Macrophages
CRIg was cloned as part of the Secreted Protein Discov-
ery Initiative (SPDI; Clark et al., 2003) in search for homo-
logs of the junctional adhesion molecule (JAM) family.
CRIg is a type 1 transmembrane Ig superfamily member
and exists as two alternatively spliced forms. The longer
form of human CRIg, huCRIg(L), encodes both V and
C2-type terminal Ig domains (Smith and Xue, 1997;
Figure S1A), while the short form, huCRIg(S), encodes
a single V-type Ig domain. Murine CRIg (muCRIg) encodes
only one form with a single IgV-type domain (Figures 1A
and S1A). huCRIg(L) is also known as Z39Ig, a molecule
first described by Langnaese et al., (2000). Z39Ig mRNA
is expressed in human monocytes differentiated with M-
CSF and IL4 (Ahn et al., 2002) and in cDNA libraries from
human synovium, lung, and placenta (Walker, 2002). The
cytoplasmic domains of human and murine CRIg contain
consensus AP-2 internalizationmotifs, YARL andDSQALI,
respectively (Bonifacino and Traub, 2003). HuCRIg(S) and
muCRIg share 67% overall sequence homology, with
83% homology residing in the IgV domain. CRIg is most
closely related to A33 antigen and JAM-A, although se-
quence similarity is confined to a conserved stretch of res-
idues forming the Ig domain fold (results not shown). Both
human and murine CRIg are located on the X chromo-
some at position Xq12 between hephaestin and moesin.
Consistent with the two alternatively spliced forms of
human CRIg, Northern blot analysis revealed a 1.7 kB
transcript and a lesser expressed 1.4 kB transcript. The
highest levels of human transcripts were detected in the
placenta, lung, adrenal gland, heart, and liver, with lower
levels in the other organs. A single transcript of 1.4 kB
was detected in mouse liver and heart (Figure S1B).
Monoclonal antibodies were generated against human
and murine CRIg to define the expression of CRIg protein.
Human and murine CRIg were absent on peripheral blood
CD19+/B220+ B-cells, CD3+ T cells, CD56+/NK1.1+ NK
cells, and CD15+/Ly6G+ granulocytes (Figure S1). huCRIg
was absent on peripheral blood CD14+ monocytes but
was readily detected on monocyte-derived macrophages
(MDMs) by flow cytometry (Figure 1B). Similar to huCRIg,
muCRIg was absent on F4/80+ peripheral blood mono-
cytes but was detected on F4/80+ liver KCs (Figure 1B)
and a subset of resident peritoneal macrophages (Fig-
ure 1C and results not shown). Expression of huCRIg(L)
and (S) protein was confirmed as 50 and 45 K Mr proteins
on monocytes differentiated into macrophages (Fig-
ure 1C). Similarly, muCRIg was detected as a 45 K Mr gly-
coprotein in peritoneal macophages (PM). muCRIg has916 Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc.a predicted N-linked glycosylation site, and its glycosyla-
tion accounts for a 5 kDa mobility shift shown by SDS
gel-electrophoresis (results not shown).
We further analyzed CRIg expression in the liver by im-
munohistochemistry. CRIg was expressed on CD68+ KCs
in human and mouse liver (Figure 1D) and interstitial mac-
rophages in the heart (results not shown). In humans, CRIg
was also detected in adrenal glandmacrophages, alveolar
macrophages, Hofbauer cells, synovial macrophages,
and lamina propria histiocytes (results not shown). CRIg
was absent from human and mouse splenic macro-
phages, Langerhans cells, microglial cells, and bone-mar-
row-derived macrophages as well as from a variety of hu-
man and mouse monocyte/macrophage cell lines (THP-1,
RAW264.7, PU5-1.8, P388D1, WEHI-3, J774, and IC-21;
results not shown). Together, these results indicate that
CRIg is highly expressed on liver KCs as well as on sub-
sets of macrophages resident in various tissues.
CRIg Binds C3b and iC3b
The expression of CRIg on a population of highly phago-
cytic cells prompted us to explore whether CRIg was in-
volved in binding of opsonized particles. Complement
and Fc receptors have been demonstrated to mediate
phagocytosis of serum-opsonized particles (reviewed by
Aderem and Underhill, 1999; Underhill and Ozinsky,
2002). To determine whether CRIg binds to complement
C3 fragments deposited on a cell surface, sheep erythro-
cytes coated with rat IgM (E-IgM) were incubated with Ju-
rkat T cells stably transfected with huCRIg(L) in the pres-
ence or absence of C3. CRIg(L)-expressing Jurkat cells,
but not empty vector-transfected cells, formed rosettes
with E-IgM in the presence (C3+), though not absence
(C3), of C3 (Figure 2A). CRIg did not appear to be in-
volved in Fc-receptor-mediated binding since sheep
erythrocytes opsonized with only IgG did not rosette
with Jurkat-CRIg cells (results not shown).
To test whether CRIg can directly bind complement
components on cell surfaces, a soluble form of human
CRIg was generated in which the extracellular domain
of CRIg was fused to the Fc portion of human IgG1.
huCRIg(L)-Fc, but not control-Fc, fusion protein bound
to E-IgM opsonized in C3-deficient serum that was recon-
stituted with increasing concentrations of purified human
C3 (Figure 2B). Both huCRIg(S)-Fc and muCRIg-Fc were
capable of binding to E-IgM, indicating that the V-type Ig
domain was sufficient for this interaction (results not
shown).
During complement activation and particle opsoniza-
tion, C3 is cleaved into its multiple breakdown products,
each of which could serve as a binding partner for CRIg.
By ELISA, huCRIg(L)- and huCRIg(S)-Fc, but not control-
Fc, demonstrated saturable binding to C3b, iC3b
(Figure 2C), and methylated C3 (results not shown) but
not to C3, C3a, or C3d (results not shown). Similar binding
specificity was observed for extracellular domain of CRIg
lacking the Fc portion and for muCRIg-Fc (results not
shown). No binding activity was detected with C1, C2,
Figure 1. CRIg Is Selectively Expressed
on a Subpopulation of Tissue Resident
Macrophages
(A) CRIg is a single transmembrane immuno-
globulin superfamily member consisting of ei-
ther an IgV and IgC2-type domain (huCRIg(L))
or one IgV-type immunoglobulin domain (hu-
CRIg(S) and muCRIg). The signal sequence
and transmembrane domain are indicated in
purple and yellow. The scale indicates size in
amino acids.
(B) CRIg is expressed in macrophages but not
in monocytes. Human CD14+ monocytes and
7-day monocyte-derived macrophages (MDM)
were analyzed for huCRIg staining by flow
cytometry using anti-huCRIg mAb (clone 3C9;
left panels, shaded histograms). Mouse F4/
80+ peripheral blood monocytes and liver KCs
were analyzed for muCRIg staining using an
anti-muCRIg mAb (clone 14G6; right panels,
shaded histograms). Open histograms: iso-
type-matched controls.
(C) Western blot analysis of whole-cell lysates
from human MDMs cultured up to 7 days and
of mouse peritoneal macrophages. Western
blots were incubated with a polyclonal anti-
CRIg antibody (left panels) or an anti-muCRIg
monoclonal antibody (right panels). Preim-
mune rabbit IgG and rat IgG2b were used as
isotype-matched controls (con). Arrows in the
left panel indicate the position of 50 and 45 K
Mr proteins; arrow in right panel indicates the
position of muCRIg protein (45 KMr). Anti-b ac-
tin was used to demonstrate equal loading.
(D) Colocalization of CRIg with CD68 on liver
KCs. Immunostaining was performed on sec-
tions obtained from human ormouse liver using
monoclonal anti-CRIg (green channel) and anti-
CD68 (red channel) antibodies. The yellow
color in the merged panels indicates colocali-
zation. Scale bar = 10 mm.C4, C4b, C5, C6, and C9 (results not shown). Conversely,
soluble C3b also bound to plate-coated huCRIg(L)-Fc and
was competed off by huCRIg(L)-ECD (results not shown).
Hence, CRIg can bind C3b and iC3b both in solution and
when bound to a substrate. Because C3b is present in
multimeric form when deposited on particle surfaces
(Hong et al., 1991) or immunoglobulins (Jelezarova et al.,
2003), we further assessed the binding of huCRIg(L) to
C3b dimers (C3b2, Arnaout et al., 1981). C3b2 bound to
huCRIg(L)-Fc with a Kd of 131 nM (results not shown)
and to huCRIg(S)-Fc with a Kd of 44 nM, as measured
by surface plasmon resonance (Figure 2D).
To complement these biochemical studies, we evalu-
ated the binding specificity of cell-surface CRIg for C3-de-
rived products. A488-labeled C3b2 bound to the surface
of CRIg(L)-expressing THP-1 cells (Figure 2E). This bind-
ing was competed off by the addition of soluble unlabeled
C3b2, C3b monomer, and huCRIg(L)-ECD, though not by
native C3. In addition to binding to soluble complementfragments, muCRIg expressed on the surface of CHO
cells also bound to various particles opsonized in C3-suf-
ficient serum (Figure S2). Together, our studies demon-
strate that both soluble and cell-surface-expressed CRIg
bind C3b and iC3b protein and opsonized particles.
CRIg Is Required for Binding of C3 Fragments
to Kupffer Cells
To study its physiological function,mice lackingCRIgwere
generated by homologous recombination (Figure S3A).
Deletion was confirmed by Southern blotting of genomic
DNA (Figure S3B), Western blotting of peritoneal macro-
phage cell lysates, and flow cytometry of KCs (Figure 3A).
CRIg knockout (ko) mice were born at the expected Men-
delian ratios and exhibited no gross phenotypic or histo-
pathological abnormalities. Absolute numbers of immune
cells in different lymphoid compartments were similar in
blood (Figure S3C), spleen, and lymph nodes (results not
shown) from wild-type (wt) and ko animals. In addition,Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc. 917
Figure 2. Cell Surface-Expressed and Soluble CRIg Bind to C3 Fragments
(A) huCRIg(L)-transfected Jurkat cells (Jurkat-CRIg, shaded histogram), but not empty vector-transfected Jurkat cells (Jurkat-control, open histo-
gram), form rosettes with E-IgM incubated with C5-depleted (C3+), though not C3-depleted (C3), serum. Results shown are representative of three
independent experiments. Scale bar = 100 mm.
(B) huCRIg(L)-Fc binding to E-IgM is C3 dependent. E-IgM, opsonized with C3-depleted human serum to which increasing concentrations of purified
human C3 were added, were incubated with a huCRIg(L)-Fc fusion protein and an anti-human Fc polyclonal antibody for flow cytometry detection.
Results shown are representative of three independent experiments.
(C) Binding of huCRIg(L)- and huCRIg(S)-Fc to C3b and iC3b. Increasing concentrations of huCRIg(L)-Fc (red symbols) and huCRIg(S)-Fc- (blue sym-
bols) or control Fc- (black symbols) fusion proteins were added to maxisorp plates coated with purified C3b or iC3b. Binding was detected using an
HRP-conjugated anti-huFc antibody and expressed in Optical Densities (O.D.) of the converted TMB substrate. Results shown are representative of
four independent experiments using different batches of fusion protein and purified complement components.
(D) Kinetic binding data showing soluble C3b dimers (C3b2) binding to huCRIg(S)-Fc. The affinity of C3b2 for the CRIg fusion proteins was determined
using surface plasmon resonance. CRIg fusion proteins were captured on a CM5 sensor chip using an antibody directed to the Fc fusion tag. C3b2
was injected for 180 s. The Kd was calculated from binding curves showing response at equilibrium plotted against the concentration. C3b2 bound to
huCRIg(S) with a calculated affinity of 44 nM and to huCRIg(L) with 131 nM affinity.
(E) C3b2, though not native C3, binds to cell surface-expressed CRIg. Left panel: histogram showing CRIg expression on huCRIg(L)-transfected
(shaded histogram), though not empty vector-transfected (open histogram), THP-1 cells by flow cytometry. Middle panel: flow cytometry analysis
of binding of A488 conjugated C3b, C3b2, and C3 to huCRIg(L)-transfected THP-1 cells following incubation for 30min at 4ºC. Right panel: C3b2 bind-
ing to THP-1 CRIg was competed off by C3b2, to a lesser extent by C3b and the extracellular domain of huCRIg(L) (CRIg ECD), and by C3 only at
higher concentrations. Results shown are representative of three independent experiments.918 Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc.
Figure 3. Expression of CRIg on Kupffer
Cells Is Required for Binding of C3b and
iC3b
(A) CRIg protein is absent on macrophages ob-
tained from CRIg ko mice. Left panel: Kupffer
Cells (KCs) from CRIg wt (red line) and ko
mice (black solid line) were incubated with
A488 conjugated 14G6 or an isotype control
antibody (dotted line) and analyzed by flow cy-
tometry. KCs were gated as indicated in Fig-
ure S3D. Right panel: peritoneal macrophages
obtained from CRIg wt, het, or ko mice were
lysed andWestern blotted with an anti-muCRIg
mAb (14G6) using anti-b-actin as a loading
control.
(B) KCs isolated from CRIg wt or ko mice ex-
press similar levels of complement receptor
CR3. KCs isolated from livers of CRIg wt and
ko mice were stained with antibody to F4/80,
CD11b, CD18 and, an isotype control (cont)
and analyzed by flow cytometry.
(C) CRIg is required for binding to C3 frag-
ments. KCs isolated from CRIg wt or ko mice
were incubated with activated mouse serum
(activated by incubation for 30 min at 37ºC) or
purified C3b, C3b2, iC3b, and PE-conjugated
anti-F4/80. Binding of C3 components to KCs
was detected by incubation with a polyclonal
anti-mouse or-human C3 antibody recognizing
the various C3-derived fragments (shaded his-
tograms). Control samples (open histograms)
were incubated with secondary antibody only.
Results shown are representative of four ex-
periments.
(D) KCs isolated from CRIg ko mice show de-
creased rosetting to mouse serum-opsonized
E-IgM. KCs isolated from livers of CRIg wt
and komice were incubated with E-IgM opson-
ized with C3-sufficient mouse serum for 30 min
at 37ºC in the presence of isotype-matched
control antibody or anti-CR3 blocking antibody
(clone M1/70, 25 mg/ml). Cells were fixed, and
the number of KCs that formed rosettes with
E-IgM were counted and expressed as a per-
centage of the total number of KCs. * = p <
0.05, Student’s t test. Results shown are repre-
sentative of two independent experiments. Im-
ages on the right depict E-IgM rosettes onCRIg
wt and ko KCs in the presence of control anti-
body. Scale bar = 50 mm.no differenceswere observed in the number of F4/80+ KCs
or heart macrophages when analyzed by flow cytometry
and immunohistochemistry, respectively (results not
shown). Expression levels of other complement binding
proteins on KCs, including the a and b chains of CR3
(CD11b and CD18), were not altered (Figure 3B). In addi-
tion, expression of complement receptor 1-related protein
y (Crry) and the low or undetectable expression of CR1,
CR2, or CD11c, the a chain of CR4, were similar between
wt and ko KCs (Figure S4A).
To analyze the binding capacity of CRIg wt and CRIg ko
KCs to C3 degradation products, C3 fragments were gen-
erated by incubation of serum at 37ºC. C3 fragments in theactivated serum as well as purified C3b2 and iC3b readily
bound to the surface of CRIg wt KCs, whereas no C3 deg-
radation fragments were bound to CRIg ko KCs (Fig-
ure 3C). Minimal binding of C3b monomer (Figure 3C)
and no binding of C3 to either wt or ko KCs were detected
(Figure S4B). To extend our analysis from the binding of
soluble C3 fragments to the binding of C3 fragments
bound to particle surfaces, we examined the requirement
for CRIg on KCs to bind mouse serum-opsonized E-IgM.
CRIg ko KCs demonstrated a 60% reduction in E-IgM
rosetting when compared to CRIg wt KCs (Figure 3D).
CR3 had a minor contribution to total binding activity, as
a further reduction (20%) in rosette formation wasCell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc. 919
Figure 4. CRIg on Kupffer Cells Recycles
(A) CRIg internalizes independently of ligand binding. KCs from C3 wt
(panels 1, 3, 4, and 6) or C3 ko mice (panels 2 and 5) were incubated
with A488-conjugated anti-CRIg antibody 14G6 or C3b2 for 1 hr at
4ºC (panels 1–3) or for 10 min at 37ºC (panels 4–6). Cells were returned
to 4ºC and incubated with (solid red) or without (solid gray) quenching
anti-A488 antibody to distinguish cytoplasmic from cell surface bound
anti-CRIg antibodies or C3b2. Open histograms show KCs incubated
with isotype-matched control antibody.
(B) CRIg, but not Lamp1, antibodies recycle to the cell surface. KCs
pooled from two mice were loaded with A488-conjugated anti-mu-
CRIg or anti-muLamp1 antibodies for 10 min at 37ºC, washed, and
subsequently incubated for indicated time periods at 37ºC in the pres-
ence of anti-A488 quenching antibodies. Mean fluorescence intensity
(MFI) was monitored by flow cytometry as a function of time. Indicated
are the mean of two independent experiments. The gray symbol and
dotted line indicate fluorescence from anti-muCRIg antibodies in the
absence of quenching antibodies.920 Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc.observed with the addition of a CR3-blocking antibody.
Hence, CRIg expression is necessary for binding of C3
degradation products and C3-opsonized particles to KCs.
CRIg Internalizes and Is Localized
on Recycling Endosomes
As binding of C3-opsonized particles to its receptors may
trigger their subsequent internalization (Fearon et al.,
1981; Sengelov et al., 1994), we applied a surface quench-
ing technique (Austin et al., 2004) to investigate whether
CRIg and C3b are internalized into KCs. A488-conjugated
anti-CRIg mAbs were preincubated with KCs at 4ºC.
Addition of anti-A488 antibodies at 4ºC quenched most
fluorescence from surface-bound A488-conjugated anti-
CRIg antibodies (Figure 4A, panel 1). When A488-conju-
gated anti-CRIg mAbs were incubated with KCs at 37ºC
for 15 min followed by incubation with anti-A488 anti-
bodies on ice, fluorescence was not quenched (Figure 4A,
panel 4), indicating that the anti-CRIg antibodies had inter-
nalized during the 37ºC incubation and were no longer ac-
cessible to quenching antibodies. Similar results were
found for the internalization of C3b2 (Figure 4A, panels 3
and 6). Internalization of anti-CRIg antibodies was not de-
pendent on the presence of C3 since uptake of the anti-
body occurred similarly in KCs isolated from C3 ko mice
(Figure 4A, panels 2 and 5). When KCs preloaded with
A488-conjugated anti-CRIg antibodies were incubated
at 37ºC in the presence, though not in the absence, of ex-
tracellular quenching antibodies, a decrease in fluores-
cence over time was observed, suggesting that anti-
CRIg antibodies recycle back to the cell surface
(Figure 4B). The time course of recycling was again inde-
pendent of C3, as the kinetics of quenching was similar
in the presence or absence of C3 (results not shown). In
contrast, A488-conjugated antibodies to the lysosomal
protein Lamp1 were internalized but did not appreciably
recycle, remaining mostly unquenched with time. Immu-
nofluorescent microscopy further confirmed the colocali-
zation of anti-CRIg antibodies and C3b2 on cytoplasmic
vesicles in KCs fromCRIg wt, but not ko, mice (Figure 4C).
These results indicate that CRIg functions as a receptor
for C3b and is located on a pool of constitutively recycling
membranes.
To further determine the subcellular compartments in
which CRIg recycles, huMDMs were visualized by epi-
fluorescence microscopy using transferrin as a marker
for recycling endosomes and Lamp1 as a marker for lyso-
somes. MDMs cultured for 7 to 12 days express CRIg
on 50% of the cells and demonstrate saturable binding
of C3b, but not of C4b (Figure S5A), that can be com-
peted off with the extracellular domain of huCRIg(L)
(C) Internalization and colocalization of CRIg and C3b2 in CRIg wt,
but not CRIg ko, KCs. KCs isolated from the livers of CRIg wt and ko
mice were cultured in chamber slides for 2 days and incubated with
A555-conjugated anti-CRIg (14G6) antibodies and A488-conjugated
C3b2 for 30 min at 37ºC, mounted in DAPI containing mounting me-
dium, and photographed. Scale bar = 10 mm.
(results not shown). Macrophages labeled with anti-CRIg
antibody at 4ºC (to prevent internalization) demonstrate
focal CRIg expression in F-actin rich filopodial extensions
(arrowheads in Figure 5A). In addition, the CRIg antibody
colocalized with C3b on the cell surface (results not
shown). Transfer of cells from 4ºC to 37ºC for 10 min
resulted in rapid internalization of CRIg antibody and
C3b into transferrin+ endosomes located in the periphery
of the cell (Figure 5B, arrows), clearly distinct from the
more perinuclear Lamp1+ lysosomal compartment (Fig-
ure S5C, arrows). CRIg remained almost completely colo-
calized within the transferrin compartment and was not
significantly accumulated in lysosomes in the presence
of lysosomal protease inhibitors even after prolonged
chase times of up to 24 hr (results not shown). Internalized
CRIg antibodies completely overlapped with the total
steady-state pool of CRIg detected postfixation with
a polyclonal antibody, indicating that the addition of anti-
CRIg antibodies did not influence CRIg recycling (Fig-
ure S5D, panels 1–3). CRIg trafficking was indepen-
dent of the presence of C3 in the medium (Figure S5D,
panel 4). Together, these results further support the con-
clusion that CRIg is present on recycling and early endo-
somes and that CRIg internalizes and recycles constitu-
tively independently of C3-derived ligand or anti-CRIg
antibodies.
Since the majority of in vivo C3b and iC3b is deposited
on particles (Brown, 1991), we next explored the distribu-
tion of CRIg in macrophages during phagocytosis of C3-
opsonized particles. Upon encounter with C3 containing
serum-opsonized E-IgM, CRIg rapidly (within 10 min) re-
distributed from transferrin-positive vesicles to the phago-
cytic cups (arrowhead in Figure 5C) and phagosomes (ar-
rows in Figures 5C and S5E) forming around the engulfed
erythrocytes. This redistribution was absent when the E-
IgMwere opsonized in C3-depleted human serum (results
not shown). During this initial stage of phagocytosis,
CRIg+ phagosomes were located in the periphery of the
cell, away from the perinuclear Lamp1+ lysosomal com-
partment (Figure 5C, arrows), and were devoid of trans-
ferrin, suggesting active sorting of CRIg to the forming
phagosome membrane. After incubation for 2 hr, these
phagosomes had matured, as determined by the colocal-
ization of the E-IgM with the Lamp1+ lysosomal compart-
ment (Figure 5D, arrowheads). Whereas CRIg continued
to be expressed on the earlier phagosomal membranes
surrounding some of the C3-opsonized E-IgM (Figure 5D,
thin arrows), most of the Lamp1+ phagosomes lacked
CRIg. The complete absence of CRIg from the Lamp1+
membranes was unlikely the result of lysosomal degrada-
tion of CRIg because lysosomal protease inhibitors were
continuously present during the incubation. Furthermore,
in macrophages containing only mature (Lamp1+) phago-
somes, CRIg colocalized with the transferrin+ compart-
ment (Figure 5D, thick arrows), suggesting that CRIg re-
turns to the recycling compartment prior to (or during)
fusion of the E-IgM-containing phagosome with the lyso-
somal compartment.Taken together, these results indicate that CRIg is ac-
tively recruited from recycling endosomes to sites of
C3b-coated particle ingestion and participates in the initial
stages of phagosome formation. CRIg then recycles from
the phagosome prior to phagosome-lysosome fusion to
return to the endosomal compartment, thus avoiding deg-
radation.
CRIg Is Required for Clearance
of C3-Opsonized Pathogens
Based on the binding of CRIg to C3b/iC3b-opsonized par-
ticles, we set out to explore a role for CRIg in the innate
response of mice to intravenously injected, complement-
opsonized bacteria. Listeria monocytogenes (LM) is an
intracellular pathogen whose major route of infection is
through the gastrointestinal tract (reviewed by Vazquez-
Boland et al., 2001; Portnoy et al., 2002; Dussurget
et al., 2004). In the present study, LMwas injected intrave-
nously to study the role of CRIg in removal of the pathogen
from the blood. In line with a role for CRIg in phagocytosis
of C3-opsonized particles, CRIg ko KCs had internalized
significantly fewer bacteria compared to CRIg wt KCs
(Figure 6A). As a result, the number of live bacteria recov-
ered in the liver of CRIg komice was significantly lower (by
9.7 million CFUs) than in CRIg wt mice, and the sum of the
bacterial counts in blood, spleen, and lung was signifi-
cantly higher (in total by 9.5 million colony-forming units
(CFUs) in CRIg ko compared to CRIg wt mice (Figure 6B).
Clearance of circulating bacteria by the liver was also
compromised in CRIg wt mice treated with a CRIg-Fc
fusion protein (Figure S6A) and in CRIg wt mice treated
with a CRIg-iC3b-blocking antibody (results not shown).
As a result of increased infection, serum cytokines were
significantly elevated in CRIg ko mice (Figure S6B). Since
bacterial counts in the nonparenchymal (NPC; KC-
enriched) and hepatocyte-enriched fractions of the livers
of both CRIg wt and ko mice were reduced by greater
than 90% during the first 6 hr following infection, in-
creased phagocytosis of bacteria by CRIg wt KCs did
not result in increased infection of the liver (Figures 6C
and S6D). The reduction in the numbers of bacteria pres-
ent in the liver cell fractions coincided with a CRIg-inde-
pendent influx of neutrophils (Figure S6C), confirming
the previously described neutrophil-dependence of LM
clearance from the liver (Pinto et al., 1991; Conlan and
North, 1994; Gregory et al., 2002). In contrast to the liver,
bacteria were not efficiently cleared from the spleen of
CRIg ko mice early following infection and, as a result,
the spleens of CRIg ko mice continued to show increased
bacterial counts compared to the spleens of CRIg wt mice
(Figures 6C and S6D). In addition, infected spleens in CRIg
ko mice showed a 5-fold reduction in splenocyte numbers
by day 6 post infection (Figure S6E), demonstrating the
functional consequence of inefficient clearance of circu-
lating bacteria in the absence of CRIg. Finally, CRIg ko
mice suffered increased mortality compared to wt mice
when infected with LM at three different doses (Figure 6D).
Thus, through retention of circulating C3-opsonizedCell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc. 921
Figure 5. CRIg Is Localized at the Plasma Membrane and on Endosomes that Are Recruited to Sites of Particle Ingestion
(A) Cell surface-expressed CRIg is concentrated at F actin-positive membrane ruffles. Monocyte-derived macrophages cultured for 7–12 days were
incubated at 4ºC with A488 conjugated anti-CRIg mAb 3C9 (panel 1 and green channel in panel 3), fixed, permeabilized, and counterstained with
A546-conjugated phalloidin (panel 2 and red channel in panel 3). Arrowheads indicate membrane ruffles where both CRIg and F-actin staining are
more intense than over the rest of the cell surface (yellow in the merged images in panel 3). Scale bar = 20 mm.
(B) CRIg and C3b colocalize with transferrin in endosomes. Macrophages were incubated for 1 hr on ice with anti-CRIg monoclonal antibody (panel 1,
red channel in panel 4) or A488-conjugated C3b (panel 2, green channel in panel 4), washed, and then chased for 10 min at 37ºC in the presence of
A647-conjugated transferrin (panel 3, blue channel in panel 4). Cells were incubated with a secondary Cy3-conjugated donkey anti-mouse Fab’2 an-
tibody following fixation and permeabilization to visualize the anti CRIg antibody. Arrows indicate colocalization of CRIg, C3b, and transferrin in an
endosome. Scale bar = 20 mm or 10 mm (insets).922 Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc.
bacteria in the liver, CRIg contributes to efficient clearance
of LM from the circulation, preventing infection of other or-
gans and promoting survival of the host.
Since complement opsonization is an important first-
line immune defense against Staphylococcus aureus
(SA) infection (Cunnion et al., 2004), we next determined
whether CRIg plays a role in complement dependent
phagocytosis of SA, an extracellular bacteriumwhose nat-
ural route of infection is through the circulation. Similar to
LM, SA activates the alternative pathway of complement,
resulting in deposition of C3b and iC3b on the pathogen
surface (Gordon et al., 1988). In C3-sufficient mice, CRIg
was required for the efficient hepatic clearance of circulat-
ing pathogens. Whereas in CRIg wt mice 91% of the bac-
teria were recovered in the liver, only 36% of the bacteria
were recovered in the liver of CRIg komice. The remainder
of the inoculum was distributed over blood, spleen, and
heart (Figure 7A). In contrast, clearance of circulating bac-
teria in C3-deficient mice was independent of CRIg status,
confirming a role of CRIg as a receptor for C3b and iC3b
bound to the pathogens surface. CRIg-dependent binding
and uptake of SA by liver KCs were further demonstrated
by flow cytometry analysis of hepatic cell fractions
(Figure 7B) and immunohistochemistry on liver sections
(Figure 7C). Thus, CRIg expression on KCs plays a domi-
nant role in complement C3-dependent removal of both
intracellular and extracellular pathogens from the circula-
tion immediately following systemic infection.
DISCUSSION
CRIg Is Required for Capture of C3-Opsonized
Pathogens by KCs
Rapid clearance of bacteria from the circulation is a crucial
step in the first-line innate immune defense against sys-
temic infection. In this study, we identify a novel comple-
ment receptor of the Ig superfamily, CRIg, which is highly
expressed on KCs and subsets of other tissue resident
macrophages, binds to the C3b and iC3b opsonins, and
is required for the rapid removal of pathogens from the cir-
culation. The structure and cellular distribution of CRIg dif-
fer from the known complement receptors. CRIg lacks
combined C3b and C4b binding short consensus repeat
sequences found in CR1 and CR2 as well as the integ-
rin-like domains present in CR3 and CR4. Whereas
CR1–CR4 are expressed on a wide variety of cell types,
CRIg expression is confined to tissue resident macro-
phages, including liver KCs.CRIg’s dual binding activity to C3b and iC3b and its
abundant expression on liver KCs mediate the efficient
capture of intravenously injected LM and SA that are
opsonized with both C3 degradation components (Gor-
don et al., 1988; Croize et al., 1993). Rapid capture of
pathogens in the liver is of crucial importance to prevent
systemic bacteremia (Hirakata et al., 1991). Once con-
tained by the liver, the pathogens are efficiently elimi-
nated, in part through killing by infiltrating neutrophils
(Pinto et al., 1991; Rogers and Unanue, 1993; Conlan
and North, 1994; Gregory et al., 1996; Ebe et al., 1999;
Gregory et al., 2002). Next to elimination by neutrophils,
there may be additional mechanisms by which LM is
cleared from the liver. A small portion of the inoculum
(0.1%) was recovered in the gal bladder (results not
shown), indicating that some of the LM captured by the
liver may be cleared by subsequent biliary excretion in
the gastrointestinal lumen (Briones et al., 1992). Inefficient
clearance of circulating pathogen leads to an increased
LM burden in blood, in turn resulting in increased infection
of the spleen where neutrophils are not able to efficiently
kill LM (Conlan and North, 1994). The central role of KCs
in clearance of circulating pathogens has been shown in
studies in which KC depletion results in impaired clear-
ance of LM from the circulation (Pinto et al., 1991; Gregory
et al., 2002). Our study now demonstrates that CRIg is the
dominant receptor on KCs that mediates complement-
dependent clearance of the pathogen from the circulation.
CRIg Recycles on Endosomes
Endosomes play a central role in endocytosis, process
elongation, and sorting and delivery of proteins to various
subcellular compartments (Steinman et al., 1983). The ex-
pressionofCRIgon recyclingendosomesensuresa readily
available supply of CRIg on the cell surface for binding to
C3-opsonized particles. CRIg-expressing endosomes are
rapidly recruited to sites of particle contact, where they
may aid in deliveringmembrane to the forming phagosome
(AderemandUnderhill, 1999;Bajnoet al., 2000;Scott et al.,
2003; Braun et al., 2004; Stuart and Ezekowitz, 2005).
The subcellular localization and intracellular trafficking
of CRIg differ from known complement C3 receptors.
Whereas CRIg is localized on constitutively recycling en-
dosomes, CR1, CR3, and CR4 are located on secretory
vesicles that fuse with the plasma membrane upon cyto-
kine stimulation of the cells and internalize ligand through
a macropinocytotic process only after crosslinking of
the receptor (Carpentier et al., 1991). The constitutive(C) CRIg is recruited to the forming phagosome. Macrophages were incubated with A488-conjugated anti-CRIg antibodies for 20min at 37ºC (panel 1
and green channel in panel 4) then incubated with E-IgM opsonized with C3-sufficient human serum for 10 min at 37ºC in the presence of A647-con-
jugated transferrin (panel 2 and blue channel in panel 4). Cells were stained with A555-conjugated antibodies to Lamp1 post fixation and permeabi-
lization (panel 3 and red channel in panel 4). Arrows indicate localization of CRIg in the forming phagosome; arrowhead indicates the presence of
a CRIg-positive phagocytic cup. Scale bar = 20 mm (shown in D).
(D) CRIg is absent in lysosomes. Macrophages were incubated with E-IgM opsonized with C3-sufficient serum for 2 hr at 37ºC in the presence of
A647-conjugated transferrin (panel 2 and blue channel in panel 4). Following fixation and permeabilization, cells were stained with polyclonal anti-
bodies to CRIg (panel 1 and green channel panel 4) and Lamp1 (panel 3 and red channel in panel 4). Thin arrows show erythrocyes in phagosomes
colocalizing with CRIg, but not with transferrin. Arrowheads show erythrocytes in mature phagosomes colocalizing with Lamp1, but not with CRIg.
Thick arrows indicate colocalization of CRIg with transferrin and not with erythrocytes. Scale bar = 20 mm.Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc. 923
Figure 6. Mice Lacking CRIg Are More Susceptible to Listeria monocytogenes Infection
(A) Reduced uptake of Listeria monocytogenes (LM)-A488 by CRIg-deficient KCs. Mice were infected with 2  107 CFUs live A488-conjugated LM.
One hour later, KCs were isolated, incubated with PE-conjugated anti-F4/80, sorted by flow cytometry, and collected on poly-L-lysine-coated slides
for observation by confocal microscopy. The number of internalized A488-conjugated LM (arrows, green channel) was counted, and the phagocytic
index was calculated. Over 95% of the LMwas found inside and not on the surface of the KCs as determined by confocal microscopy. Data represent
mean ± SD of four animals per group. Results are representative of three experiments. Statistical analysis (Student’s t test): **p < 0.001. Scale bar =
10 mm.
(B) Decreased Colony Forming Units (CFUs) in liver and increased bacterial counts in blood, spleen, and lung in CRIg ko mice 10 min following in-
travenous injection of LM (2  107 CFUs). CFUs are expressed per organ or per total pool of peripheral blood. Indicated in a table below the graph
are the average numbers of bacteria in each compartment. Data represent mean ± SD of 5–6 animals per group. Statistical analysis (Student’s t test):
*p < 0.05, **p < 0.005, ***p < 0.001.
(C) LM is rapidly cleared from the liver independent of CRIg status. The liver nonparenchymal cell fraction (NPC) and the hepatocyte-enriched fraction
(Hep) were separated, and bacterial counts were determined at 10 min and 6 hr following injection of LM (1 107 CFU). CFUs are expressed per total
cells in the fractions. Over 90% of LM was cleared from the liver during the first 6 hr following infection. Data represent mean ± SD of 4–5 animals per
group. Statistical analysis (Student’s t test): **p < 0.005.
(D) Decreased resistance of CRIg ko mice to LM infection. Survival curves of CRIg wt (red lines) and CRIg ko (black lines) mice infected with the in-
dicated doses of LM following injection into the lateral tail vein; n = 5 per group. Statistical analysis (Wilcoxon): wt versus ko p < 0.005 for 2 104 and
2  105 colony-forming units (CFUs); p < 0.001 for 5  104 CFUs.924 Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc.
Figure 7. CRIg Is Involved in C3-Depen-
dent Clearance of Staphylococcus au-
reus from the Circulation
(A) Decreased bacterial counts in liver and in-
creased bacterial counts in blood, spleen,
and heart in C3-sufficient CRIg ko mice 10
min following intravenous injection with Staph-
ylococcus aureus (SA) (5 107 CFU). In C3-de-
ficient mice, bacterial counts in the organs or
total pool of peripheral blood in CRIg wt and
CRIg ko mice are equivalent. Indicated are
mean ± SD for 7–10 animals per group. Statis-
tical analysis (Student’s t test): *p < 0.0001.
(B) Reduced binding of A488-labeled SA to
CRIg-deficient KCs. Mice were injected with
2  107 CFU live A488-conjugated SA. Liver
cells were isolated 1 hour later, incubated
with various combinations of antibodies to F4/
80, CD45, and CD31, and analyzed by flow cy-
tometry. Kupffer cells were identified as F4/80+
cells, endothelial cells as CD45 CD31+ cells,
and hepatocytes by forward and side scatter.
The histograms are representative of three in-
dependent experiments.
(C) Fluorescence micrograph showing de-
creased phagocytosis of SA by Kupffer cells
from CRIg ko mice. Mice were infected as de-
scribed for Figure 7B; liver was fixed 1 hour
later; sections were stained with anti-F4/80
and DAPI and visualized by fluorescence mi-
croscopy. The number of A488-conjugated
SA inside KCs (arrows) were counted, and the
phagocytic index was calculated. Data repre-
sent mean ± SD of three animals per group.
Statistical analysis (Student’s t test): *p <
0.05. Scale bar = 10 mm.recycling of CRIg and its endocytosis of ligand in resting
macrophages fit with a role in binding of complement-
opsonized particles during the initial phase of a bacterial
infection prior to generation of an inflammatory response
(e.g., the recruitment of activated phagocytes). In addi-
tion, CRIg may be involved in the constitutive removal of
C3-opsonized apoptotic cells and cell debris, thus pre-
venting local inflammation. How CRIg expression on
phagocytes is regulated during an inflammatory response
and whether CRIg synergizes with other complement re-
ceptors in binding to C3-opsonized particles are areas
of future investigation.
In summary, this study identifies a novel macrophage
receptor that constitutes an important component of the
innate immune system by bridging the central comple-
ment component C3 with acute clearance of pathogens.
This finding further stresses the critical role of complement
and tissue resident macrophages as the first line of im-
mune defense against circulating pathogens.
EXPERIMENTAL PROCEDURES
Cloning and Characterization of Human and Murine CRIg
huCRIg(L) and (S) were cloned from a human fetal library using primers
to the Ig folds of A33 antigen. A partial murine CRIg (muCRIg) se-quence was assembled from an EST library, and full-length muCRIg
was obtained using primers directed to the 30 and 50 UTR. Fusion pro-
teins were generated as described in Supplemental Experimental Pro-
cedures.
Antibodies and Generation of Stably Transfected Cells
All antibodieswere purchased fromBDPharmingen except for anti-F4/
80 (Caltag), anti-human CD68 (clone KP-1, Dako), anti-mouse CD68
(clone FA-11, Serotech), and FITC-conjugated polyclonal antibody to
mu or huC3 (MP Biomedicals). Cell lines expressing CRIg and mono-
clonal antibodies to mu and huCRIg were generated as described in
Supplemental Experimental Procedures.
Immunohistochemistry
Human liver, collected and snap-frozen at autopsy, was obtained from
Ardais Corporation. Liver tissue from 3-month-old CD-1 mice was col-
lected, snap-frozen, and embedded in Optimal Cutting Temperature
compound (OCT, Tissue-Tek, Miles Laboratories) at necropsy. For im-
munohistochemistry, 6 mmcryostat sections obtained from human and
mouse liver were incubated with directly conjugated anti-CRIg and
anti-CD68 antibodies.
Complement Proteins and Complement-Deficient Serum
Complement C3 was isolated according to the method of Hammer
et al. (1991) with an additional protein A column to remove contaminat-
ing IgGs. See Supplemental Experimental Procedures for details on
the generation of C3 fragments. All other complement proteins and
C3- and C5-depleted human serum were purchased from CompTech.Cell 124, 915–927, March 10, 2006 ª2006 Elsevier Inc. 925
iC3b was purified over a Superdex S-200 10/300 GL gel filtration col-
umn to separate monomers from dimers.
Analysis of CRIg Binding to C3 Fragments
C3 or C3 fragments (4 mg/ml) were adsorbed to Maxisorp plates (Nal-
gene-Nunc) overnight at 4ºC. The plate was blocked with PBS, pH 7.4,
containing 1%BSA for 2 hr at 22ºC, washed 3with PBS, pH 7.4, con-
taining 0.05% Tween-20 (PBS-T), and incubated with 100 ul serially di-
luted CRIg proteins for 1 hr at 22ºC. Bound CRIg was detected with
a 1/3000 dilution of HRPO-conjugated goat anti-human-IgG Ab (Cal-
tag). Detection was visualized with 100 ul TMB (KPL), and the reaction
was stopped with 50 ul 2N H2SO4. Optical density (O.D.) was mea-
sured at 450 nm. All Abs and CRIg proteins were diluted in PBS-T at
100 ml/well. Analysis of the interaction between C3b and CRIg using
surface plasmon resonance and flow cytometry analysis of CRIg recy-
cling was performed as described in Supplemental Experimental Pro-
cedures.
Immunofluorescence Microscopy and Phagocytosis
Culturing of MDMs, recycling, and phagocytosis assays were per-
formed as described in Supplemental Experimental Procedures.
Animals
All animals were held under Sterile Pathogen Free conditions and
housed in a 14 on, 10 hr off light/dark cycle with food and water avail-
able ad infinitum. Animal experiments were approved by the Institu-
tional Animal Care and Use Committee of Genentech. CRIg/C3 single-
and double-ko mice were generated as described in Supplemental
Experimental Procedures.
Microorganisms
Maintenance, inoculation, and phagocytosis of SA (ATCC strain
10832) and LM (ATCC strain 43251) were performed as described in
Supplemental Experimental Procedures.
Supplemental Data
Supplemental Data include seven figures, Experimental Procedures,
and References and can be found with this article online at http://
www.cell.com/cgi/content/full/124/5/915/DC1/.
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